2022-500921-34-00
Completed
Phase 1
A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose
Achieve Life Sciences Inc.7 sites in 2 countries56 target enrollmentStarted: October 24, 2022Last updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Achieve Life Sciences Inc.
- Enrollment
- 56
- Locations
- 7
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Daniel Cain
Scientific
Achieve Life Sciences Inc.
Study Sites (7)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications2023-506227-29-00AbbVie Deutschland GmbH & Co. KG60
Recruiting
Phase 1
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)2024-512089-32-00ADC Therapeutics SA121
Recruiting
Phase 1
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)2023-507377-17-00Microbiotica Limited27
Completed
Phase 1
A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.2023-506661-65-00Bristol-Myers Squibb Services Unlimited Company40
Not yet recruiting
Phase 1
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors2024-516870-31-00Merck Sharp & Dohme LLC14